APIM Therapeutics secures venture funding.
The following article about Birk Venture was published at Oslo Cancer Cluster:
Birk Venture is delighted to announce a new investment in the Norwegian based oncology company Targovax
APIM Therapeutics is chosen to present at the
Bio-Europe Spring 2012 which this year will be held in Amsterdam 19-21 March. Read more
Capital funding of BerGenBio in Norwegian media.
Birk Venture - office adress: Karenslyst allé 8b, 0278 Oslo Norway phone: +47 90 87 14 83 mail: firstname.lastname@example.org